Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Its news flow centers on the clinical and regulatory progress of its lead drug candidate, PrimeC, a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, in a fixed dose designed to target multiple disease mechanisms.
News updates for NRSN commonly cover milestones in ALS and Alzheimer’s clinical programs. These include Phase 2 and Phase 2b trial readouts, such as the PARADIGM study in ALS and the RoAD proof-of-concept study in Alzheimer’s disease, along with biomarker analyses that the company uses to interpret treatment effects. Press releases also highlight safety and tolerability findings, including reports of favorable safety profiles and absence of new or unexpected safety signals in clinical studies.
Investors and observers can expect coverage of regulatory interactions, such as FDA clearance to initiate a pivotal Phase 3 trial of PrimeC in ALS, database lock announcements for Alzheimer’s trials, and updates on planned submissions to agencies like Health Canada. Corporate and financing developments, including private placements of ordinary shares and business updates, are also frequent topics.
This news page aggregates these company-issued announcements, SEC-related communications and other public disclosures about NeuroSense’s progress. It is useful for readers who want to follow NRSN’s clinical trial milestones, biomarker-driven research updates, regulatory steps and capital-raising activities as the company advances PrimeC in ALS and Alzheimer’s disease.
NeuroSense (NASDAQ: NRSN) reported extended PARADIGM Phase 2b survival data showing a median survival of 36.3 months with continuous PrimeC versus 21.4 months for initial placebo, an improvement of over 14 months (~70% increase).
Adjusted analysis showed a 65% reduction in risk of death (HR 0.35; 95% CI 0.17–0.71; p=0.0037) and a statistically significant log-rank p=0.0218. The randomized 68-patient trial included a 2:1 active:placebo double-blind period and an open-label extension; company engagement with regulators continues.
NeuroSense (Nasdaq: NRSN) announced that IP Australia granted Australian Patent No. 2022370513 for compositions comprising ciprofloxacin and celecoxib, extending patent protection for PrimeC through October 2042.
The grant follows a corresponding U.S. patent (12,097,185) and strengthens the company’s global exclusivity strategy as PrimeC advances toward pivotal Phase 3 development in ALS after positive Phase 2b PARADIGM results and FDA clearance of the Phase 3 protocol.
NeuroSense (NASDAQ: NRSN) announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 12,527,768 for a PrimeC combination therapy for Alzheimer's disease, extending patent protection through 2043. The patent covers compositions combining an anti-inflammatory drug and a Dicer activator for neuronal diseases, which the company says strengthens its intellectual property for long-term development and potential commercialization.
NeuroSense also completed a proof-of-concept Alzheimer's study (RoAD) with top-line results showing a favorable safety and tolerability profile. Clinical and biomarker outcomes from the study are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) announced that Prof. Steven E. Arnold, a noted Alzheimer's expert and Professor of Neurology at Harvard Medical School, has joined its Scientific Advisory Board.
The company said Prof. Arnold brings biomarker-driven clinical development and translational neuroscience experience as NeuroSense advances its PrimeC programs in ALS and Alzheimer's disease. NeuroSense reported that its proof-of-concept Alzheimer's study (RoAD) showed a favorable safety and tolerability profile, and that clinical and biomarker outcomes from RoAD are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) reported completion of the safety analysis from its Phase 2 randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC in Alzheimer's disease on Dec 22, 2025.
The safety review found a favorable tolerability profile, with no serious adverse events reported and no new or unexpected safety signals identified. Clinical outcome measures in this exploratory proof-of-concept study are descriptive by design.
NeuroSense will analyze clinical observations together with biomarker data to aid interpretation, and full clinical and biomarker results are expected in Q1 2026.
NeuroSense (NASDAQ: NRSN) said it is resuming regulatory activity in Canada for PrimeC in amyotrophic lateral sclerosis (ALS) after a productive discussion with Health Canada.
Health Canada outlined remaining requirements and confirmed NeuroSense's proposed next steps align with the Agency's expectations. The company is preparing for a pre‑NDS meeting currently contemplated in April 2026. With additional clinical data recently generated and further analyses underway, NeuroSense said it anticipates a potential NDS submission by mid‑2026, pending a successful meeting and completion of final submission components.
NeuroSense will provide more details at an investor webinar on December 8, 2025.
NeuroSense (Nasdaq: NRSN) announced that the U.S. Food and Drug Administration completed review of its IND amendment and authorized initiation of the pivotal Phase 3 trial PARAGON evaluating PrimeC in amyotrophic lateral sclerosis (ALS) on Nov 24, 2025. PARAGON is planned as a global, double-blind, 12-month, placebo-controlled study with 300 participants randomized 2:1 (PrimeC:placebo), an open-label extension, an adaptive design with interim analyses, and is powered at >95% for its primary endpoint. NeuroSense aims to enroll the first patient in the coming months subject to securing strategic resources. Additional trial details and timelines will be presented at an investor webinar on Dec 8, 2025.
NeuroSense (NASDAQ: NRSN) will host an investor webinar on December 8, 2025 at 8:30 a.m. ET to provide business, regulatory and clinical updates.
Planned topics include the Phase 3 PARAGON study initiation (ALS), submission for Notice of Compliance with conditions (NOC/c) in Canada, the status of a binding term sheet executed in December 2024, and updates on the RoAD Phase 2 program (Alzheimer's disease). Investors can register to attend the webcast.
NeuroSense (NASDAQ: NRSN) reported Phase‑2b plasma biomarker results for PrimeC on October 6, 2025 showing statistically significant reductions in multiple Alzheimer's‑linked microRNAs. Key measured reductions from baseline include miR‑21‑5p (p=0.003), miR‑146a‑5p (p=0.007), miR‑let‑7e‑5p (p=0.006) and miR‑let‑7a‑5p (p=0.028), while placebo showed no significant changes over time. The company said these miRNA changes reflect reduced neuroinflammatory and neurodegenerative activity and support PrimeC's potential as a disease‑modifying therapy. NeuroSense indicated the data will inform design of a follow‑on Alzheimer's study and that Phase‑3 readiness for PrimeC in ALS remains ongoing.
NeuroSense Therapeutics (NASDAQ:NRSN) has reported positive initial results from its Phase 2 RoAD clinical trial of PrimeC for Alzheimer's disease. The study, conducted in collaboration with NeuroKaire, demonstrated that PrimeC enhanced neuroplasticity in patient-derived neurons while showing no treatment-related toxicity.
Using NeuroKaire's proprietary technology, which converts patient blood samples into brain cells, researchers observed improvements in brain-cell connectivity and health. The ongoing Phase 2 trial is a randomized, double-blind, placebo-controlled study evaluating PrimeC in mild-to-moderate Alzheimer's patients over 12 months.